Heterogeneous her2 amplification—a new clinical category of her2-positive breast cancer?

Abstract

HER2 amplification heterogeneity is associated with resistance to trastuzumab emtansine in the neoadjuvant setting, emphasizing the importance of assessing whether heterogeneous HER2-positive cancers require different treatment pathways.